ArticleActa paediatrica (Oslo, Norway : 1992)2026
Health Economic Evaluation of Varicella Vaccination Within the Swedish National Vaccination Programme for Children.
Article in Acta paediatrica (Oslo, Norway : 1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Modelling Impact of Different Varicella Immunisation Strategies Upon Introduction in the Swedish National Programme.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Health Economic Evaluation of Varicella Vaccination Within the Swedish National Vaccination Programme for Children.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Rationale for Recommending Varicella Vaccination Into the Swedish National Immunisation Programme.Acta paediatrica (Oslo, Norway : 1992) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo assess the cost-effectiveness of including varicella vaccination in the Swedish national vaccination programme for children together with the added impact of catch-up vaccination of susceptible older children.
methodsAn epidemiological transmission model was used to assess the cost-effectiveness of a two-dose national varicella vaccination programme, with and without a catch-up strategy, compared to no varicella vaccination. Parameter estimates were based on scientific publications and data from Swedish national and regional registries.
resultsA national varicella vaccination programme would result in health gains and cost-savings from a societal perspective. Cost-savings were primarily due to a reduction in caregiver productivity loss. From a health system perspective, the cost per quality-adjusted life-year gained was estimated at around SEK 200 000 (EUR 18 000), both with and without catch-up vaccination. At a negotiated vaccine price reduction to 30% of the current list price, the cost per quality-adjusted life-year gained would come down to SEK 5 000 (EUR 450).
conclusionOur analyses suggest that inclusion of varicella vaccination in the national vaccination programme for children would be a cost-saving strategy from a societal perspective, which together with a catch-up vaccination offer for susceptible older children would result in a fast decline of varicella in Sweden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.